# Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

> **NCT04507906** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Chest Hospital** · enrollment: 21 (actual)

## Conditions studied

- NSCLC Stage IV
- Checkpoint Inhibitor

## Interventions

- **DRUG:** Nivolumab Combined with Anlotinib

## Key facts

- **NCT ID:** NCT04507906
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04507906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04507906, "Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04507906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*